Abstract:Monoamine transporters including transporters for serotonin, dopamine, and norepinephrine play key roles in monoaminergic synaptic signaling, involving in the molecular etiology of a wide range of neurological and physiological disorders. Despite being crucial drug targets, the study of transmembrane proteins remains challenging due to their localization within the cell membrane. To address this, we present the structural bioinformatics studies of 7 monoamine transporters and their water-soluble variants designed using the QTY code, by systematically replacing the hydrophobic amino acids leucine (L), valine (V), isoleucine (I) and phenylalanine (F) with hydrophilic amino acids (glutamine (Q), threonine (T) and tyrosine (Y). The resulting QTY variants, despite significant protein transmembrane sequence differences (44.27%-51.85%), showed similar isoelectric points (pI) and molecular weights. While their hydrophobic surfaces significantly reduced, this change resulted in a minimal structural alteration. Quantitatively, Alphafold2 predicted QTY variant structures displayed remarkable similarity with RMSD 0.492Å-1.619Å. Accompanied by the structural similarities of substituted amino acids in the context of 1.5Å electron density maps, our study revealed multiple QTY and reverse QTY variations in genomic databases. We further analyzed their phenotypical and topological characteristics. By extending evolutionary game theory to the molecular foundations of biology, we provided insights into the evolutionary dynamics of chemically distinct alpha-helices, their usage in different chemotherapeutic applications, and open possibilities of diagnostic medicine. Our study rationalizes that QTY variants of monoamine transporters may not only become distinct tools for medical, structural, and evolutionary research, but these transporters may also emerge as contemporary therapeutic targets, providing a new approach to treatment for several conditions.

Monoamine transporters: vulnerable and vital doorkeepers.

Structure-Based Specific Detection And Inhibition Of Monoamine Oxidases And Their Applications In Central Nervous System Diseases

Regulation of monoamine transporters: Role of transporter phosphorylation

General Overview of Organic Cation Transporters in Brain

Recent Advances and Challenges of the Drugs Acting on Monoamine Transporters.

Post-translational mechanisms in psychostimulant-induced neurotransmitter efflux

SLC6 neurotransmitter transporters: structure, function, and regulation

SLC6 transporters: Structure, function, regulation, disease association and therapeutics

Kinase-dependent Regulation of Monoamine Neurotransmitter Transporters

Organic cation transporter 3: Keeping the brake on extracellular serotonin in serotonin-transporter-deficient mice

Review : Serotonin Transporter and Psychiatric Disorders: Listening to the Gene

Synaptic uptake and beyond: the sodium- and chloride-dependent neurotransmitter transporter family SLC6

Multifaceted Regulations of the Serotonin Transporter: Impact on Antidepressant Response

Regulated phosphorylation and trafficking of antidepressant-sensitive serotonin transporter proteins

Interaction of antidepressants with the serotonin and norepinephrine transporters: mutational studies of the S1 substrate binding pocket

Structural bioinformatics studies of serotonin, dopamine and norepinephrine transporters and their AlphaFold2 predicted water-soluble QTY variants and uncovering the natural mutations of L->Q, I->T, F->Y and Q->L, T->I and Y->F

Dimerization and antidepressant recognition at noradrenaline transporter

The Solute Carrier Transporters and the Brain: Physiological and Pharmacological Implications.

The Functional Impact of SLC6 Transporter Genetic Variation

Mechanisms of neurotransmitter transport and drug inhibition in human VMAT2

Modifying 5-HT1A receptor gene expression as a new target for antidepressant therapy